“…Two things interesting were that, the ORR of CT053 to treat the RRMM patients relapsed after three or more LOT with the extramedullary disease (EMD) being 91.7%, the CR rate being 58.3%, and the median PFS being 9.3 months, better than the results of those past treatment strategies such as combination therapy with permadomide and dexamethasone (ORR: 30%; CR rate: 15.3%) ( 69 ) and carfilzomib-based combination therapy (ORR: 27%, CR rate: 0%, median PFS: 5 months) ( 70 ). For the patients with high-risk cytogenetic abnormalities [del(17p), t(4;14), t(14;16)/1q21], the ORR and CR rate of CT053 were 84.2% and 73.3%, respectively, with the 15.6 months median PFS, better than the results of ishatuximab, permadomide, and dexamethasone combination (ORR: 50%, CR rate: 0%, median PFS: 7.5 m) ( 71 ), carfilzomib monotherapy (ORR: 25.8%, CR rate: 0%, median PFS: 3.5 m) ( 72 ), and even the infusion of bb2121 (ORR: 73%, CR rate: 33%, median PFS: 8.2 m) ( 60 ). Secondly, the relationship between the dosage and curative effect of C-CAR088 has been studied ( 52 ).…”